R&D News | pharmaphorum

News

Foundation stone ceremony at Orano Med's ATLab plant in France, set to be the first industrial-scale pharma facility in Europe for lead-212 isotopes

Sanofi invests €300m in Orano Med's lead-based radioligands

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclea

News

Sage cuts a third of its workforce after R&D setbacks

Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.

News

Cell segmentation stain of human skin using the xenium cell segmentation antibody panel

First human skin atlas points way to healing without scars

Researchers have created a map of human skin that uses genomics and other technologies to understand how skin forms and the mechanisms behind skin disorders.

News

Colourised transmission electron micrograph of mpox virus particles

NIH study backs Bavarian Nordic mpox jab for adolescents

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in

News

Wave Life Sciences president and CEO Paul Bolno

Wave surges on first RNA editing data in humans

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).

News

Head and neck cancer trials 'becoming less diverse'

Despite efforts in the US to increase the diversity of clinical trials, a study has found that in one form of cancer the trend seems to be going in the other direction.

Sanofi invests €300m in Orano Med's lead-based radioligands

Sage cuts a third of its workforce after R&D setbacks

First human skin atlas points way to healing without scars

NIH study backs Bavarian Nordic mpox jab for adolescents

Wave surges on first RNA editing data in humans

Head and neck cancer trials 'becoming less diverse'

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks